Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
09:25am, Tuesday, 29'th Apr 2025
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clin
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Avis
ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy
07:00am, Tuesday, 29'th Apr 2025
ST. PAUL, Minn. , April 29, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awar
Shareholder Alert: Robbins LLP Informs Investors of the Avis Budget Group, Inc. Class Action Lawsuit
09:48pm, Monday, 28'th Apr 2025
SAN DIEGO , April 28, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Avis Budget Group
Pomerantz Law Firm Announces the Filing of a Class Action Against Avis Budget Group, Inc. and Certain Officers - CAR
06:46pm, Monday, 28'th Apr 2025
NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Avis Budget Group, Inc. ("Avis Budget" or the "Company") (NASDAQ: CAR) and certai
CAR Investors with Losses in Excess of $100K Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit
06:39pm, Monday, 28'th Apr 2025
NEW YORK , April 28, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Avis Budget Group,
CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
05:32pm, Monday, 28'th Apr 2025
LOS ANGELES , April 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Avis Budget Group, Inc. ("Avis Bu
NEW YORK CITY, NY / ACCESS Newswire / April 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Avis
CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
11:41am, Monday, 28'th Apr 2025
LOS ANGELES--(BUSINESS WIRE)--CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Avis Budget Group, Inc. (NASDAQ
ATLANTA, April 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Avis Budget Group, Inc. (“Avis Budget” or “the Company”) (NASDAQ: CAR). The lawsuit allege
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Avis Budget class action lawsuit seeks to represent purchasers or acquirers of Avis Budget Group, Inc.
5 Broker-Loved Stocks to Keep a Tab on Amid Signs of Easing Trade Woes
10:25am, Thursday, 24'th Apr 2025
Investors would do well to monitor broker-loved stocks like CAR, ABM, CVI, DK and ABG for high returns.
Avis Budget Group to Announce First Quarter 2025 Results on May 7th
04:01pm, Thursday, 17'th Apr 2025
PARSIPPANY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its first quarter 2025 results after the market close on Wednesday, M
SAN JOSE, Calif. , April 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
